Why is meloxicam included on the Beers criteria for older adults?

Why Meloxicam is on the Beers Criteria

Meloxicam is included on the Beers Criteria because, as a non-selective NSAID, it significantly increases the risk of gastrointestinal bleeding, peptic ulcers, and acute kidney injury in older adults—risks that outweigh its analgesic benefits compared to safer alternatives. 1

Primary Risks in Older Adults

The 2019 AGS Beers Criteria explicitly lists meloxicam among NSAIDs that should be avoided in older adults due to:

• Gastrointestinal toxicity: Increased risk of bleeding and peptic ulcer disease, occurring in approximately 2-4% of older adults using NSAIDs 1
• Renal injury: Higher risk of acute kidney injury and reduced kidney function 1
• Cardiovascular effects: Potential to worsen heart failure and increase blood pressure 1

The recommendation to avoid meloxicam carries a strong strength of recommendation with high-quality evidence 1

Why Older Adults Are More Vulnerable

Older adults face disproportionate harm from meloxicam because:

• They are more likely to be taking anticoagulants or antiplatelet agents, which compounds bleeding risk 1
• Age-related decline in kidney function makes them more susceptible to NSAID-induced nephrotoxicity 1
• Concurrent use of corticosteroids (common in this population) further elevates gastrointestinal bleeding risk 1

High-Risk Situations Requiring Absolute Avoidance

The Beers Criteria specifically emphasizes avoiding NSAIDs including meloxicam in older adults with:

• Heart failure (particularly reduced ejection fraction) - NSAIDs can worsen fluid retention and cardiac function 1
• History of peptic ulcer disease or GI bleeding - even with gastroprotective agents like proton-pump inhibitors 1
• Chronic kidney disease - NSAIDs accelerate renal decline 1
• Concurrent anticoagulant or antiplatelet therapy - dramatically increases bleeding risk 1

Important Caveats

While meloxicam is marketed as a "preferential" COX-2 inhibitor with theoretically lower GI risk than non-selective NSAIDs 2, the Beers Criteria treats it as a non-selective NSAID for practical purposes. Research shows meloxicam has greater gastrointestinal risk than highly specific COX-2 inhibitors 2, placing it in the same risk category as traditional NSAIDs like ibuprofen and naproxen.

The long half-life of meloxicam (approximately 20 hours) 2, 3 means that adverse effects, once they occur, persist longer than with shorter-acting NSAIDs—a particular concern when managing complications in frail older adults.

Clinical Application

The Beers Criteria is not meant to be punitive but rather educational 1. However, when prescribing decisions involve pain management in older adults:

• First-line alternatives: Acetaminophen (if no contraindications), topical NSAIDs, or non-pharmacologic approaches should be prioritized 4
• If systemic NSAIDs are absolutely necessary: Use the lowest effective dose for the shortest duration possible, with gastroprotection 1
• Never use in high-risk patients: Those with the conditions listed above should not receive meloxicam regardless of gastroprotection 1

The 2023 update maintains these recommendations, reinforcing that meloxicam remains a potentially inappropriate medication for most older adults 5.